Abstract
The aims of this study were to evaluate the effects of fampridine on verbal fluencies in MS patients and to compare the supposed cognitive effect with the gait effect. Our study was a prospective monocentric open label trial. Thirty-one MS patients were included (42% primary progressive MS, 45% secondarly progressive MS, 13% relapsing-remitting MS) with a mean EDSS of 5.43. Assessments of verbal phonological and semantic fluencies were repeated twice (within one week) before fampridine treatment, and twice after fampridine treatment. Gait velocity was measured before and after fampridine treatment. Post-hoc analyses were performed in order to limit the impact of the practice effect. Verbal fluencies were significantly improved by fampridine treatment ( P < 0.05). Phonological fluency showed greater improvement than semantic fluency after fampridine treatment. No significant difference on verbal fluency performance was observed between gait responders and non-responders groups. The results suggest a specific cognitive effect of treatment with fampridine. There is an improvement in verbal influences mainly phonological, which implies an action on executive functions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
